Inflammation, high-sensitivity C-reactive protein, and vascular protection

Texas Heart Institute Journal

Volumn 37, Issue 1, 2010, Pages 40-41

  Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; METHOTREXATE; PLACEBO; RAPAMYCIN; ROSUVASTATIN;

ANGIOPLASTY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CORONARY ARTERY DISEASE; CORONARY STENT; EDITORIAL; HEART INFARCTION; HIGH RISK PATIENT; IN-STENT RESTENOSIS; INFLAMMATION; PROGNOSIS; PUBLICATION; RISK REDUCTION; VASCULAR DISEASE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CIRCADIAN RHYTHM; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STENTS; TREATMENT OUTCOME;

EID: 77950400453     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Editorial

References (8)

1. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25(10):567-79.
2. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207.
3. Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009;55(2):378-84.
4. Koc M, Karaarslan O, Abal G, Batur MK. Variation in high-sensitivity C-reactive protein levels over 24 hours in patients with stable coronary artery disease. Tex Heart Inst J 2010;37 (1):42-8.
5. Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990;82(3):897-902.
6. Glynn RJ, MacFadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem 2009;55(2):305-12.
7. Li JJ, Ren Y, Chen KJ, Yeung AC, Xu B, Ruan XM, et al. Impact of C-reactive protein on in-stent restenosis: a meta-analysis. Tex Heart Inst J 2010;37(1):49-57.
8. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009;7 Suppl 1:332-9.